Literature DB >> 28109898

Composite particles based on particle engineering for direct compaction.

Zhe Li1, Xiao Lin2, Lan Shen3, YanLong Hong4, Yi Feng4.   

Abstract

Direct compaction (DC) is the preferred method for tablet production. However, only a minority of the active pharmaceutical ingredients (APIs) can be truly manufactured into tablets by DC so far due to that most of APIs lack sufficient functional properties required for DC. Particle engineering with co-processing provides a promising way to obtain various composite API and/or excipient particles with markedly improved functional properties, which makes successful tableting of them by DC possible. This review, as an informative update and supplement, covers the improvement of functional properties of composite API and/or excipient particles via co-processing based on recent developments and researches in the area of particle engineering for DC. The improved functionality of co-processed particles and corresponding mechanisms were summarized and discussed from the perspective of structure characteristics (Crystal level and Particle level) as the properties of particles are markedly affected by their structure.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Co-processing; Composite particles; Direct compaction; Functional properties; Particle engineering; Tablet

Mesh:

Substances:

Year:  2017        PMID: 28109898     DOI: 10.1016/j.ijpharm.2017.01.030

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  2 in total

1.  Development on porous particles of Pueraria lobatae Radix for improving its compactibility and dissolution.

Authors:  MiaoMiao Zhou; YouJie Wang; Fei Wu; Lan Shen; Xiao Lin; Yi Feng
Journal:  RSC Adv       Date:  2018-07-04       Impact factor: 3.361

2.  The Novel Use of PVP K30 as Templating Agent in Production of Porous Lactose.

Authors:  Wei-Feng Zhu; Lin Zhu; Zhe Li; Wen-Ting Wu; Yong-Mei Guan; Li-Hua Chen; Zhi-Xuan Mao; Liang-Shan Ming
Journal:  Pharmaceutics       Date:  2021-05-30       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.